6:02 AM
 | 
Dec 11, 2017
 |  BC Extra  |  Preclinical News

Histone modifier is implicated in epithelial-mesenchymal transition

In a paper published in the Journal of Cell Biology, researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) identified a histone modifier that may regulate epithelial-mesenchymal transition (EMT), a process associated with tumor cell invasiveness and chemotherapy resistance.

The Genentech team, led by VP of Cancer Immunology Ira Mellman, sought to identify epigenetic regulators of...

Read the full 269 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >